AbCellera Biologics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABCL Nasdaq 2830 www.abcellera.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbCellera Biologics Inc.

What Could Go Wrong With Recursion Pharmaceuticals Stock? - Oct 8th, 2026 5:58 pm
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting - Oct 8th, 2026 2:05 pm
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 - Oct 1st, 2026 2:05 pm
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment - Oct 1st, 2026 10:11 am
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight - Sep 30th, 2026 8:31 am
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? - Sep 29th, 2026 8:57 pm
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know - Sep 22nd, 2026 8:17 am
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 - Sep 16th, 2026 2:05 pm
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 - Sep 2nd, 2026 2:05 pm
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity - Aug 15th, 2026 7:09 pm
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - Aug 14th, 2026 4:53 pm
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - Aug 12th, 2026 10:05 pm
AbCellera (ABCL) Q2 2026 Earnings Call Transcript - Aug 12th, 2026 6:31 pm
AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed? - Aug 12th, 2026 1:10 am
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal - Aug 12th, 2026 12:14 am
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results - Aug 11th, 2026 3:11 pm
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Aug 11th, 2026 2:01 pm
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data - Aug 11th, 2026 9:13 am
Is AbCellera Biologics (ABCL) Fully Valued After Its 172% Run? - Aug 11th, 2026 4:10 am